Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00495573
Other study ID # 26224-A
Secondary ID P01AI030731R01AI
Status Completed
Phase N/A
First received June 29, 2007
Last updated March 21, 2012
Start date June 2007
Est. completion date March 2012

Study information

Verified date March 2012
Source University of Washington
Contact n/a
Is FDA regulated No
Health authority United States: Institutional Review Board
Study type Observational

Clinical Trial Summary

The purpose of the study is to evaluate the pattern of viral shedding after beginning treatment with acyclovir for a clinical recurrence of genital herpes and to compare it with the pattern of viral shedding during an untreated clinical recurrence of genital herpes.


Description:

The purpose of the study is to evaluate the pattern of viral shedding after beginning treatment with acyclovir for a clinical recurrence of genital herpes and to compare it with the pattern of viral shedding during an untreated clinical recurrence of genital herpes.

Participants are asked to visit the University of Washington Virology Research Clinic for an initial screening appointment in which the clinician will ensure eligibility and informed consent will be obtained.

Participants who experience an outbreak during the next year will be asked to call the clinic at the beginning of their next outbreak. The clinician will arrange to admit the participant to the UW General Clinical Research Center (GCRC) for a 5-day hospitalization stay. During hospitalization, participants will take acyclovir (400mg 3 times daily) and genital swabs will be collected every 2 hours during the day and every 4 hours at night for 5 days. After the last swab has been taken, the study nurse at the GCRC will do a final genital exam and the participant will be discharged. Some participants will also be asked to enroll in a control arm during which the same procedures will be followed except they will not take acyclovir during the recurrence.


Recruitment information / eligibility

Status Completed
Enrollment 36
Est. completion date March 2012
Est. primary completion date November 2009
Accepts healthy volunteers No
Gender Both
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Age 18 years or older

- History of clinically-evident genital herpes

- 3 or more clinical genital herpes recurrences within the prior 12 months

- HSV-2 seropositive by HSV Western Blot

- Willing and able to comply with study protocol

Exclusion Criteria:

- Pregnancy

- Taking daily antiviral therapy for genital herpes

- HIV seropositive or known immunocompromising medical condition

- Plan to move from the Seattle area within the next year

- Hypersensitivity to or intolerance of acyclovir

Study Design

Observational Model: Case-Only, Time Perspective: Prospective


Related Conditions & MeSH terms


Intervention

Drug:
acyclovir
400 mg acyclovir, orally three times a day for 5 days

Locations

Country Name City State
United States University of Washington Virology Research Clinic Seattle Washington

Sponsors (2)

Lead Sponsor Collaborator
University of Washington National Institutes of Health (NIH)

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary To calculate the half-life of detectable HSV-2 DNA in genital mucosa during a clinical recurrence of genital herpes, after treatment with acyclovir has begun. 5 days No
Secondary To describe the time course, diurnal variation, and pattern of resolution of HSV-2 shedding during both acyclovir-treated and untreated clinical recurrences of genital herpes. 5 days No
See also
  Status Clinical Trial Phase
Active, not recruiting NCT06033261 - A Study of mRNA-1608, a Herpes Simplex Virus -2 (HSV-2) Therapeutic Candidate Vaccine, in Healthy Adults 18 to 55 Years of Age With Recurrent HSV-2 Genital Herpes Phase 1/Phase 2
Completed NCT00362297 - Randomized Trial to Evaluate Suppressive Effect of High-Dose Acyclovir Versus Once-Daily Valacyclovir on Persons With HSV-2 Phase 4
Completed NCT01132729 - Bioequivalency Study of Valacyclovir Hydrochloride 1000 mg Under Fasting Conditions N/A
Completed NCT01132716 - Bioequivalency Study of Valacyclovir Hydrochloride 1000 mg Under Fed Conditions N/A
Completed NCT03831165 - Melatonin Effects on Genital Herpes in Brazilian Women Phase 4
Terminated NCT01658826 - Safety and Efficacy Comparator Trial of a New Drug Against Genital Herpes Phase 2
Completed NCT00262106 - Trial to Evaluate PRO 2000/5 Gels for the Prevention of Vaginally Acquired HIV Infection Phase 3
Completed NCT01346475 - Randomized Trial to Evaluate Suppressive Effect of High-Dose Valacyclovir Versus Once-Daily Valacyclovir on Persons With HSV-2 Phase 4
Completed NCT01390805 - Special Drug Use Investigation for VALTREX (Valaciclovir) (Suppression Prophylaxis) N/A
Terminated NCT03146403 - Maintenance Dose Study of GEN-003 in Subjects With Genital Herpes Infection Phase 2
Completed NCT03080961 - The VIBLOK SAfety and perFormancE Trial N/A
Completed NCT00231049 - Trial Evaluating Safety, Tolerability and Immune Response of AG-707 Phase 1
Completed NCT00306787 - Efficacy and Safety of Famciclovir 1-day Treatment Compared to 3-day Treatment With Valacyclovir in Adults With Recurrent Genital Herpes Phase 3
Completed NCT00477334 - Patient-initiated Episodic Treatment of Recurrent Genital Herpes in Black Patients Phase 4
Not yet recruiting NCT03595995 - A Phase 2 Trial to Evaluate the Safety and Efficacy of UB-621 Phase 2
Completed NCT01281007 - Efficacy of Oral Famciclovir 125mg Comparing to Aciclovir 200 mg Treatment in Patients With Active Recurrent Genital Herpes Phase 3
Completed NCT01112956 - Serologic Assays for the Diagnosis of Herpes Simplex Virus Type 2 N/A
Completed NCT00129818 - A Study to Evaluate the Effect of Famciclovir in Reducing Herpes Virus Shedding Phase 4
Completed NCT00808405 - GUD Clinical and Virologic Response to Acyclovir in HIV Negative African Women N/A
Terminated NCT00495716 - Effect of HSV-2 Suppressive Therapy on Sexual Behavior Phase 4